|
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Deverra Therapeutics, Inc. (Deverra Therapeutics) was selected by the Andy Hill CARE Fund, Washington's Cancer Research Endowment, for two Life Science Start-Up and Development Awards. The recipients of the Life Science Start-up and Development awards were announced by the CARE Fund on June 8th following a competitive peer scientific review and selection process.
The grant funds totalling close to $3.5 million will be used to support further pre-clinical work and product development plans for Deverra's CAR-NK and engineered myeloid cell programes in hematologic malignancies and solid tumours, respectively. Coeptis recently completed an exclusive license of key assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.
The Life Science Start-up and Development grant was established by The Andy Hill Cancer Research Endowment (CARE) Fund to support early-stage companies and innovative researchers to translate promising research into the development of tools, devices, or therapeutics related to cancer The Andy Hill CARE Fund, signed into law in 2015 strives to leverage Washington's existing cancer research facilities and talent to incentivize additional investment and to advance the biotech, medical device, and health care information technology industries in Washington. \
"This competitive Life Science Start-Up award from the prestigious Andy Hill CARE Fund further acknowledges the high-level, innovative and important research that Deverra is progressing through pre-clinical/IND-enabling and clinical trials," said Dave Mehalick, president and CEO of Coeptis Therapeutics. "We congratulate the Deverra research and management teams and are excited by the potential to build synergies with Deverra's allogeneic, off-the-shelf NK and macrophage (MAC) immune effector cell platform and Coeptis' target specific CARs, which together potentially create opportunities to develop allogeneic NK and MAC cell therapies."
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
|